Last reviewed · How we verify
HCG is introduced
HCG is introduced is a Small molecule drug developed by Servy Massey Fertility Insititute. It is currently in Phase 1 development. Also known as: Improve results of IVF and embryo transfer.
HCG is a hormone that has been studied in various clinical trials for conditions such as Human Papillomavirus (HPV), cervical cancer, and infertility. However, the exact mechanism of HCG is unknown, according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HCG is introduced |
|---|---|
| Also known as | Improve results of IVF and embryo transfer |
| Sponsor | Servy Massey Fertility Insititute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer (NA)
- Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
- Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
- Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women (PHASE3)
- Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient (NA)
- Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF (NA)
- G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score (PHASE2, PHASE3)
- A Study:the Different Outcomes Between Natural Cycle and Hormone Replacement Cycle in FET (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCG is introduced CI brief — competitive landscape report
- HCG is introduced updates RSS · CI watch RSS
- Servy Massey Fertility Insititute portfolio CI
Frequently asked questions about HCG is introduced
What is HCG is introduced?
Who makes HCG is introduced?
Is HCG is introduced also known as anything else?
What development phase is HCG is introduced in?
Related
- Manufacturer: Servy Massey Fertility Insititute — full pipeline
- Also known as: Improve results of IVF and embryo transfer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing